echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > The profit of the pharmaceutical manufacturing industry increased by nearly 90% in the first half of the year, and pharmaceutical companies handed in satisfactory answers

    The profit of the pharmaceutical manufacturing industry increased by nearly 90% in the first half of the year, and pharmaceutical companies handed in satisfactory answers

    • Last Update: 2021-08-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    In recent years, with the improvement of people's living standards, increased investment in public health, and the increasing degree of population aging, the pharmaceutical market has developed rapidly in China


    According to the data released by the National Bureau of Statistics on July 27, in the first half of 2021, the national pharmaceutical manufacturing industry achieved a year-on-year increase of 28.


    In addition, according to the semi-annual report data released by major companies, many companies have ushered in gratifying results


    According to the report, in the first half of 2021, Harbin Pharmaceutical Group's operating income increased by 33.


    On August 16, Lifang Pharmaceutical also disclosed its semi-annual report.


    On the same day (August 16th), Neptunus Biology also issued a semi-annual report stating that its operating income in the first half of 2021 increased by 13.


    In addition, in terms of Chinese medicine companies, many companies also submitted satisfactory answers in the first half of the year


    Some analysts pointed out that with the maturity of the domestic pharmaceutical industry environment, domestic pharmaceutical companies have set off an upsurge of innovation.


    In addition, according to the research and development progress of the research project announced by Betta Pharmaceuticals, its first-line treatment of ALK-positive NSCLC patients with Ensatinib hydrochloride is already in the Pre-NDA stage in the United States and will be declared for marketing in the United States in 2021; multi-target RTKs inhibitor CM082 The indication for the treatment of metastatic renal cell carcinoma that has failed the previous VEGFR-TKI first-line treatment is currently in clinical II/III, and a marketing application will be submitted in China this year


    In addition, in the first half of this year, the total R&D investment of Enhua Pharmaceuticals and Mike Biology exceeded 100 million yuan, 157 million yuan and 111 million yuan respectively; the total R&D investment of Yuandong Biology, Aide Biology, and Weiss Medical accounted for the proportion of revenue.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.